GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

In wake of the recent tragic events at the Lapu Lapu Festival in Vancouver, the BC Association of Clinical Counsellors (BCACC) is offering a free public webinar ? 'Caring for Ourselves & our ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 5.76%, which has investors questioning if this is right time to buy.

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...